Atomoxetine hydrochloride

@article{Garland2004AtomoxetineH,
  title={Atomoxetine hydrochloride},
  author={Melissa R. Garland and Peter Kirkpatrick},
  journal={Nature Reviews Drug Discovery},
  year={2004},
  volume={3},
  pages={385-386}
}
In November 2002, atomoxetine hydrochloride (Strattera; Eli Lilly), a noradrenaline-reuptake inhibitor, was approved by the US FDA for the treatment of attention-deficit–hyperactivity disorder. As the first non-stimulant drug for this common but controversial condition, and also the first approved for the treatment of adults, what influence has it had on the market since its introduction? 
4 Citations
10 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 10 references

<http://www.fda.gov/cder/foi/label/2002/21411_strattera_ lbl.pdf>

  • W SNE, I SANALYS
  • FDA Drug Approvals List [online],
  • 2004

Attention deficit/hyperactivity disorder across the lifespan

  • Wilens, E T.
  • Annu. Rev. Med
  • 2002

integrating clinical and basic neuroscience research

  • Solanto, M. V. Dopamine dysfunction in ADHD
  • Behav. Brain Res. 130, 65–71
  • 2002

Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder

  • T Spencer
  • Am. J. Psychiatry 155,
  • 1998

Clinical pharmacology of tomoxetine, a potential antidepressant

  • Zerbe, L R.
  • J. Pharmacol. Exp. Ther. 232,
  • 1985

Similar Papers

Loading similar papers…